Report on the 28th Joint Symposium of the Japan Mucopolysaccharidosis Patients' Family Association and Japan Mucopolysaccharidosis Study Group

(August 23, 2025 in Tokyo)

A total of 130 participants attended, including patients, their families, medical professionals, doctors, pharmaceutical companies, and government officials.

Presentations featured patient families sharing their voices, and physicians discussing the current status of expanded mass screening 19 years after the approval of mucopolysaccharidosis treatment drugs. Following this, patient groups and physicians engaged in a focused discussion on challenges related to the brain, bones, and eyes, exchanging opinions for future directions. Venture companies presented cutting-edge treatment technologies, and government officials talked in special lectures about pharmaceutical safety management and government initiatives to promote the development of Japan's drug discovery ecosystem. The diverse range of speakers made this a highly meaningful learning opportunity, enabling active exchange of opinions.

We would like to express our sincere appreciation to SSIEM for their grant, which enabled this event to be held successfully. The grant was used to cover venue fees, printing costs, and volunteer expenses. We greatly appreciate the support from SSIEM.